The earnings call reflected both positive and negative trends. The Specialty Pharma business showed strong growth, particularly in products like Okedi and heparin, and the company is expanding its technological capabilities. However, overall revenue decreased due to significant declines in the CDMO segment, and profitability metrics like EBITDA and net profit also fell. The company's strategic focus on long-term growth and innovation is evident, but immediate financial challenges persist.

Company Guidance

During the call detailing ROVI's first half of 2025 financial results, the company reiterated its guidance that operating revenue would decrease by a mid-single-digit percentage compared to 2024. While total operating revenue fell 4% to EUR 314.6 million, impacted by a 35% decline in CDMO sales, the Specialty Pharma business saw a 13% increase to EUR 237.4 million. Notably, Okedi sales surged by 115% to EUR 26.9 million, and the Heparin division, led by enoxaparin, grew 12% to EUR 135.2 million. Gross margin improved by 3 percentage points to 62.4%, despite a 6% EBITDA decline due to higher R&D expenses. The company continues to invest heavily in R&D, with expenses up 38% to EUR 16.8 million, as it advances its ISM technology platform. Despite the challenges, ROVI remains optimistic about its growth trajectory, particularly in its Specialty Pharma and CDMO segments, supported by strategic investments and a strong European footprint.

Specialty Pharma Business Growth

Sales of the Specialty Pharma business increased by 13% to EUR 237.4 million in the first half of 2025, driven by products like Okedi, Neparvis, and heparin divisions.

Okedi Sales Surge

Okedi sales increased by 115% to EUR 26.9 million in the first half of 2025 compared to the same period in 2024, showing a robust growth trajectory.

Heparin Division Performance

The heparin division saw a 12% sales increase to EUR 135.2 million, with enoxaparin sales rising 14% due to stronger international sales.

Gross Margin Improvement

Gross margin increased by 3 percentage points to 62.4% in the first half of 2025, driven by product mix and reduced raw material costs.

Technological Development and Innovation Center Aid

Award of aid of EUR 36.3 million for ROVI's LAISOLID project, covering development costs from January 2023 to August 2026.

Expansion in AI and Pathological Anatomy

Acquired a majority position in Cells IA Technologies, enhancing ROVI's capabilities in AI-assisted diagnosis for pathological anatomy.

Laboratorios Farmaceuticos Rovi (GB:0ILL) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

GB:0ILL Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Nov 06, 2025	2025 (Q3)	- / -	0.86	―	―	―
Jul 24, 2025	2025 (Q2)	- / 0.42	0.86	-50.81% (-0.44)	―	―
May 08, 2025	2025 (Q1)	- / 0.35	0.289	22.49% (+0.07)	―	―
Feb 25, 2025	2024 (Q4)	- / 0.46	0.994	-54.02% (-0.54)	―	―
Nov 07, 2024	2024 (Q3)	- / 1.36	0.978	39.47% (+0.39)	―	―
Jul 31, 2024	2024 (Q2)	- / 0.86	0.36	138.89% (+0.50)	―	―
May 08, 2024	2024 (Q1)	- / 0.29	0.889	-67.49% (-0.60)	―	―
Feb 27, 2024	2023 (Q4)	- / 0.99	1.464	-32.10% (-0.47)	―	―
Nov 08, 2023	2023 (Q3)	- / 0.98	0.797	22.71% (+0.18)	―	―
Jul 26, 2023	2023 (Q2)	- / 0.36	0.51	-29.41% (-0.15)	―	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

GB:0ILL Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Jul 24, 2025	€54.39	€56.54	+3.95%
May 08, 2025	€50.50	€53.02	+4.99%
Feb 25, 2025	€54.50	€54.26	-0.44%
Nov 07, 2024	€74.28	€65.45	-11.89%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Laboratorios Farmaceuticos Rovi (GB:0ILL) report earnings?

Laboratorios Farmaceuticos Rovi (GB:0ILL) is schdueled to report earning on Nov 06, 2025, TBA (Confirmed).

What is Laboratorios Farmaceuticos Rovi (GB:0ILL) earnings time?

Laboratorios Farmaceuticos Rovi (GB:0ILL) earnings time is at Nov 06, 2025, TBA (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is the P/E ratio of Laboratorios Farmaceuticos Rovi stock?

The P/E ratio of Laboratorios Farmaceuticos Rovi is N/A.

What is GB:0ILL EPS forecast?

Currently, no data Available

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing